This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (52)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

J. MARTIN MILLER, MD; ROBERT C. HORN, MD; MELVIN A. BLOCK, MD

Arch Intern Med. 1964;113(1):72-88.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In 1913 Plummer differentiated exophthalmic goiter from toxic adenomatous goiter on the basis of clinical observations on 2,000 operated cases.¹ He recognized that the former might be superimposed on any stage of endemic goiter, with resultant problems in differential diagnosis that might be difficult to resolve on either clinical or pathological grounds.² That this problem is present 50 years later is clearly attested by literature relating to the treatment of hyperthyroidism with I¹³¹. In these writings the term toxic nodular goiter is often used to describe any case of hyperthyroidism occurring in a nodular gland as judged by the inclusion of patients with actual exophthalmos in this category.^3,4 Other authors use it in a more restricted sense to describe only non-Graves' hyperthyroidism.⁵

We describe two groups of patients without clinical features of Graves' disease (exophthalmic goiter) as toxic nodular goiter: first, those with a solitary nodule . . . [Full Text PDF of this Article]

Author Affiliations
DETROIT

Henry Ford Hospital.

Footnotes
Received for publication July 3, 1963; accepted July 29.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?